Virtual Reality and Congenital Diaphragmatic Hernia

November 9, 2022 updated by: Maged Basha, Qassim University

Virtual Reality-based Exercises' Effects on Pulmonary Functions, Cardiopulmonary Capacity, Functional Performance, and Quality of Life in Children With Repaired Congenital Diaphragmatic Hernia

The study has been designed to investigate the effect of 12 weeks of using virtual reality based exercises on pulmonary functions, exercise capacity, functional performance, and quality of life in children with surgically-repaired congenital diaphragmatic hernia.

Study Overview

Detailed Description

Children with CDH have significant disruptions in their quality of life (QoL) due to their poor health, in this randomized controlled clinical trial, one important aspect of virtual reality is the interactivity of children and their interests in choosing the exercised game. Each child in two groups perform a specific virtual reality based respiratory exercises for 3 months.

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Riyadh
      • Al-Kharj, Riyadh, Saudi Arabia, 11432
        • Outpatient Clinic of College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

4 years to 8 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 6 and 10 years.
  • BMI was between 20 and 24 kg/m2.
  • surgically-repaired congenital diaphragmatic hernia.
  • respiratory distress symptoms.
  • under follow-up care in pediatric and physical therapy clinic.

Exclusion Criteria:

  • Children were excluded if they have growth abnormality.
  • neuromotor disorders.
  • children with cardiac problems.
  • unable to do understand all procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Traditional physical therapy program
For 15 minutes, each child in both groups perform the following specific respiratory exercises: resistance-based diaphragm strengthening exercises, breathing exercises.
resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
Experimental: Virtual reality-based exercises
Following a session of traditional physical therapy, the children in study group toke 30 minutes rest then they joined in a 30-minute VR exercise session using Nintendo Wii systems.
resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary function test, forced expiratory volume in the first second
Time Frame: From date of randomization (first week of intervention)
A pulmonary function test was conducted for all participants using a spirometry analyzer (Autospiro-507; Minato Medical Science; Osaka. Japan).
From date of randomization (first week of intervention)
Pulmonary function test, forced expiratory volume in the first second
Time Frame: after 12 weeks
A pulmonary function test was conducted for all participants using a spirometry analyzer (Autospiro-507; Minato Medical Science; Osaka. Japan).
after 12 weeks
Pulmonary function test, forced vital capacity
Time Frame: From date of randomization (first week of intervention)
A pulmonary function test was conducted for all participants using a spirometry analyzer (Autospiro-507; Minato Medical Science; Osaka. Japan).
From date of randomization (first week of intervention)
Pulmonary function test, forced vital capacity
Time Frame: after 12 weeks
A pulmonary function test was conducted for all participants using a spirometry analyzer (Autospiro-507; Minato Medical Science; Osaka. Japan).
after 12 weeks
Pulmonary function test, FEV1/FVC ratio
Time Frame: From date of randomization (first week of intervention)
performed using a spirometer (Autospiro-507; Minato Medical Science; Osaka. Japan)., (forced expiratory volume in the first second/ forced vital capacity) FEV1/FVC ratio was recorded.
From date of randomization (first week of intervention)
Pulmonary function test, FEV1/FVC ratio
Time Frame: after 12 weeks
performed using a spirometer (Autospiro-507; Minato Medical Science; Osaka. Japan)., (forced expiratory volume in the first second/ forced vital capacity) FEV1/FVC ratio was recorded.
after 12 weeks
Exercise capacity assessment
Time Frame: From date of randomization (first week of intervention)
Cardiopulmonary pulmonary exercise test using the Bruce treadmill test was used to asess the exercise capacity.
From date of randomization (first week of intervention)
Exercise capacity assessment
Time Frame: after 12 weeks
Cardiopulmonary pulmonary exercise test using the Bruce treadmill test was used to asess the exercise capacity.
after 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional performance assessment
Time Frame: From date of randomization (first week of intervention)
Functional performance was assessed through using the 6-min walk test.
From date of randomization (first week of intervention)
Functional performance assessment
Time Frame: after 12 weeks
Functional performance was assessed through using the 6-min walk test.
after 12 weeks
Pediatric Quality of Life Inventory
Time Frame: From date of randomization (first week of intervention)
Quality of life was evaluated using self-report Pediatric Quality of Life Inventory (PedsQL), it is multidimensional measures of HRQL in children and adolescents, it includes 23 items distributed among 4 domains [physical (8 items) , emotional( 5 items), social ( 5 items ), and school functions ( 3 items )] including 23 items. It provides child self-report and parents report with 5- points scale ( 0 means never, and 4 means almost always).
From date of randomization (first week of intervention)
Pediatric Quality of Life Inventory
Time Frame: after 12 weeks
Quality of life was evaluated using self-report Pediatric Quality of Life Inventory (PedsQL), it is multidimensional measures of HRQL in children and adolescents, it includes 23 items distributed among 4 domains [physical (8 items) , emotional( 5 items), social ( 5 items ), and school functions ( 3 items )] including 23 items. It provides child self-report and parents report with 5- points scale ( 0 means never, and 4 means almost always).
after 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Alshimaa Azab, PhD, Prince Sattam Bin Abdulaziz University
  • Study Chair: Ragab Elnaggar,, PhD, Prince Sattam Bin Abdulaziz University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2021

Primary Completion (Actual)

September 9, 2021

Study Completion (Actual)

April 15, 2022

Study Registration Dates

First Submitted

October 27, 2022

First Submitted That Met QC Criteria

November 9, 2022

First Posted (Actual)

November 10, 2022

Study Record Updates

Last Update Posted (Actual)

November 10, 2022

Last Update Submitted That Met QC Criteria

November 9, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

IPD Sharing Time Frame

6 months after publication

IPD Sharing Access Criteria

relevance to the topic of the study and approval of all co-authors within 1 month of receiving the request.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Informed Consent Form (ICF)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Children

Clinical Trials on Traditional physical therapy program

3
Subscribe